Torré-Muir syndrome

Torré-Muir syndrome is also known as ‘Muir-Torré syndrome’ and ‘sebaceous neoplasia/visceral carcinoma’.

What is Torré-Muir syndrome?

Torré-Muir syndrome is a rare inherited condition in which there are sebaceous (oid gland) skin tumours in association with internal cancer.

The most common organ involved is the gastrointestinal tract, with almost one half of patients having colorectal cancer. The second most common site is cancer of the genitourinary tract.

Cutaneous features

Skin lesions may occur before or after the diagnosis of the internal cancer. Sebaceous tumours are generally otherwise rare and their development should arouse suspicion of Torré-Muir syndrome and the need for more investigative tests. The sebaceous neoplasms include:

• sebaceous adenomas
• sebaceous epitheliomas
• sebaceous carcinomas.

Sebaceous hyperplasia and sebaceous naevus are not usually related to Torré-Muir syndrome.

Other skin lesions that may arise in affected family members include:

• keratoacanthoma
• squamous cell carcinoma
• multiple follicular cysts.

Cutaneous sebaceous neoplasm	Features
Sebaceous adenoma and sebaceous epithelioma	Most characteristic cutaneous marker of Torré-Muir syndrome Benign tumours appearing as yellow papules or nodules Grow all over the body but mostly located on the head, particularly on the face, scalp and eyelids
Sebaceous carcinoma	Malignant tumours that occur most commonly on the eyelids On eyelids, tumour appears as a firm, yellow nodule with a tendency to ulcerate Carcinomas on the eyelid can frequently metastasise and cause death May also occur anywhere on skin, including ears, feet, penis and labia
Keratoacanthoma	Solitary or multiple lesions frequently seen in Torré-Muir syndrome Usually starts as a red papule that rapidly grows to become a skin-coloured, shiny nodule with telangiectases (red spider-like markings caused by dilated blood vessels) and a central horny plug covered by a crust

What is the cause of Torré-Muir syndrome?

Torré-Muir syndrome is an autosomal dominant condition meaning half of an affected person's children also have the syndrome.

It is currently considered to be a subtype of the more common hereditary nonpolyposis colorectal cancer syndrome, which is due to mutations in 4 mismatch repair genes, mostly involving the MSH2 gene, located on chromosome 2p. It is likely that Torré-Muir syndrome is associated with mutations of these genes.

How is it diagnosed?

Torré-Muir syndrome is usually suspected because of the clinical features. However, if a sebaceous adenoma, a sebaceous carcinoma or colonic polyp is removed surgically, the pathologist may examine the cells to see whether the MSH gene products have microsatellite instability, a characteristic of the syndrome.

What is the treatment for Torré-Muir syndrome?

Patients with Torré-Muir syndrome need to undergo medical and physical examinations and appropriate laboratory and radiographic tests on a regular basis to check for internal malignancies, particularly of the gastrointestinal and genitourinary tracts. Patients need regular colonoscopy for early detection of colorectal tumours. Cancers should be managed with appropriate anti-cancer therapies.

In some families genetic diagnosis can identify asymptomatic carriers of the mutation. All first-degree relatives, especially mutation carriers, should be referred from the age of 20 years for routine follow-up and early treatment

Treatment of the skin lesions includes:

• Benign tumours and keratoacanthomas may be treated surgically with excision or cryotherapy
• Sebaceous carcinomas should be excised completely
• Oral retinoids, e.g. acitretin or isotretinoin, may prevent some lesions
• Interferon injections are sometimes combined with retinoid treatment